Acalabrutinib, marketed under the brand name Acaluxen 100mg, is a breakthrough medication used in the treatment of specific Blood Cancer therapy, including mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL). As a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, Acalabrutinib works by blocking the activity of BTK, a protein that contributes to the growth and survival of cancer cells. This…
Ibrucent 140 mg (Ibrutinib) is an innovative oral medication used to treat specific types of blood cancers, including Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Waldenström’s Macroglobulinemia (WM). Ibrutinib, the active ingredient in Ibrucent, is a Bruton’s Tyrosine Kinase (BTK) inhibitor. This targeted therapy blocks the activity of BTK proteins, which are crucial for the growth and survival…
Ventoxen 100mg, containing Venetoclax, is a breakthrough oral medication used to treat specific blood cancer treatment, including chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). This targeted therapy is designed to inhibit the BCL-2 protein, which plays a key role in cancer cell survival. It helps restore the body's natural ability to trigger cell death in cancerous cells. Ventoxen…
